…
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Uscom Ltd is an Australian medical technology company that develops and supplies non-invasive haemodynamic monitoring devices for clinical settings. Long-term growth may be supported by demographic trends increasing demand for cardiovascular diagnostics, wider clinical adoption of non-invasive monitoring, and expanded regulatory approvals and market access. Investors may find the company attractive because it appears positioned in a specialized niche with proprietary technology and potential for revenue expansion if adoption continues.
Principal risks include limited scale and cashflow, execution and financing risk, regulatory and reimbursement uncertainty, and competitive pressures that could constrain commercial traction.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -3.25M | -2.03M | -2.56M | -1.94M | -0.88M |
| Net income | -3.30M | -2.07M | -2.59M | -1.97M | -0.92M |
| Selling general administrative | 4.83M | 3.69M | 3.44M | 4.85M | 2.74M |
| Selling and marketing expenses | 1.09M | 1.07M | 0.95M | 0.66M | 0.63M |
| Gross profit | 2.23M | 3.12M | 2.25M | 2.91M | 3.37M |
| Reconciled depreciation | - | 0.39M | 0.38M | 0.42M | 0.40M |
| Ebit | -3.20M | -1.90M | -2.45M | -2.36M | -0.79M |
| Ebitda | -3.06M | -1.51M | -2.07M | -1.94M | -0.39M |
| Depreciation and amortization | 0.14M | 0.39M | 0.38M | 0.42M | 0.40M |
| Operating income | -3.73M | -2.38M | -2.45M | -2.36M | -0.79M |
| Other operating expenses | 6.31M | 6.13M | 5.58M | 5.19M | 5.29M |
| Interest expense | 0.13M | 0.13M | 0.10M | 0.08M | 0.10M |
| Tax provision | 0.05M | 0.05M | 0.03M | 0.03M | 0.04M |
| Interest income | 0.09M | 0.05M | 0.13M | 0.04M | 0.03M |
| Net interest income | - | -0.09M | -0.05M | -0.06M | -0.06M |
| Income tax expense | 0.05M | 0.05M | 0.03M | 0.03M | 0.04M |
| Total revenue | 2.58M | 3.73M | 2.66M | 3.25M | 3.86M |
| Total operating expenses | 5.96M | 5.52M | 5.16M | 4.85M | 4.81M |
| Cost of revenue | 0.35M | 0.61M | 0.42M | 0.34M | 0.49M |
| Total other income expense net | 0.48M | 0.35M | 0.41M | 0.42M | -0.10M |
| Net income from continuing ops | - | -2.07M | -2.59M | -1.97M | -0.92M |
| Net income applicable to common shares | -3.30M | -2.07M | -2.59M | -1.97M | -0.92M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 3.25M | 5.13M | 5.18M | 7.99M | 5.33M |
| Intangible assets | 0.01M | - | 0.50M | 0.48M | 0.47M |
| Other current assets | 0.66M | - | 0.00M | 0.40M | 0.44M |
| Total liab | 3.29M | 2.07M | 2.14M | 2.06M | 2.26M |
| Total stockholder equity | -0.04M | 3.06M | 3.04M | 5.94M | 3.08M |
| Other current liab | 0.69M | 0.68M | -0.00M | 0.20M | 0.62M |
| Common stock | 40.44M | 40.42M | 38.51M | 39.14M | 34.67M |
| Capital stock | - | - | 38.51M | 39.14M | 34.67M |
| Retained earnings | -44.88M | -41.58M | -39.50M | -36.91M | -34.94M |
| Other liab | - | - | 0.09M | 0.07M | 0.07M |
| Other assets | - | 0.00M | 0.08M | 0.08M | 0.08M |
| Cash | 0.97M | 1.05M | 2.18M | 4.70M | 1.71M |
| Cash and equivalents | - | - | 0.30M | 3.02M | 0.02M |
| Total current liabilities | 2.79M | 1.28M | 1.21M | 0.90M | 0.95M |
| Current deferred revenue | - | - | 0.67M | - | - |
| Net debt | 1.30M | -0.06M | -1.09M | -3.39M | -0.28M |
| Short term debt | 1.90M | 0.30M | 0.26M | 0.22M | 0.19M |
| Short long term debt total | 2.26M | 0.99M | 1.09M | 1.31M | 1.43M |
| Other stockholder equity | - | 0.00M | 0.10M | 3.71M | 3.35M |
| Property plant equipment | - | - | 0.86M | 1.12M | 1.33M |
| Total current assets | 2.65M | 3.87M | 3.74M | 6.31M | 3.45M |
| Net tangible assets | - | - | 2.53M | 5.45M | 2.61M |
| Short term investments | - | 1.47M | - | - | - |
| Net receivables | 0.22M | 0.72M | 0.37M | 0.34M | 0.40M |
| Inventory | 0.80M | 0.62M | 0.75M | 0.87M | 0.89M |
| Accounts payable | 0.20M | 0.30M | 0.28M | 0.48M | 0.14M |
| Accumulated other comprehensive income | 4.41M | 4.22M | 4.04M | 3.71M | 3.35M |
| Non currrent assets other | - | 0.42M | 0.08M | 0.08M | 0.08M |
| Non current assets total | 0.60M | 1.27M | 1.44M | 1.68M | 1.88M |
| Capital lease obligations | - | - | 1.09M | 1.31M | 1.43M |
| Long term debt total | - | - | 0.83M | 1.09M | 1.24M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | - | -0.06M | -0.15M | -0.12M | -0.03M |
| Change to liabilities | - | - | 0.47M | -0.02M | 0.03M |
| Total cashflows from investing activities | -0.07M | -0.06M | -0.15M | -0.12M | -0.03M |
| Net borrowings | - | - | -0.31M | -0.26M | -0.27M |
| Total cash from financing activities | 1.21M | 1.57M | -0.95M | 4.05M | -0.28M |
| Change to operating activities | - | - | -0.11M | 0.06M | -0.02M |
| Net income | -3.30M | -2.07M | -2.59M | -1.97M | -0.92M |
| Change in cash | -1.55M | 0.34M | -2.53M | 2.99M | -0.21M |
| Begin period cash flow | 2.52M | 2.18M | 4.70M | 1.71M | 1.92M |
| End period cash flow | 0.97M | 2.52M | 2.18M | 4.70M | 1.71M |
| Total cash from operating activities | -2.71M | -1.16M | -1.42M | -1.56M | 0.05M |
| Issuance of capital stock | - | 2.00M | - | 4.36M | - |
| Depreciation | 0.39M | 0.39M | 0.36M | 0.42M | 0.40M |
| Other cashflows from investing activities | -0.05M | -0.05M | - | - | - |
| Change to inventory | -0.18M | 0.13M | 0.12M | 0.02M | -0.07M |
| Change to account receivables | 0.02M | 0.06M | -0.03M | 0.00M | 0.05M |
| Sale purchase of stock | 0.00M | -0.09M | -0.64M | -0.05M | -0.01M |
| Other cashflows from financing activities | 1.57M | -1.54M | -0.31M | -0.26M | -0.27M |
| Change to netincome | - | - | 0.34M | 0.53M | 0.58M |
| Capital expenditures | 0.01M | 0.06M | 0.15M | 0.12M | 0.03M |
| Change in working capital | -0.19M | 0.38M | 0.44M | 0.71M | 0.73M |
| Stock based compensation | 0.17M | 0.23M | - | - | - |
| Other non cash items | 0.22M | -0.09M | - | 1.56M | 0.53M |
| Free cash flow | -2.72M | -1.22M | -1.58M | -1.67M | 0.02M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| UCM Uscom Ltd |
- -% |
0.01 | - | - | 1.29 | 2.16 | 1.71 | -2.72 |
| COH Cochlear Ltd |
2.26 1.50% |
152.98 | 68.64 | 27.40 | 4.30 | 5.34 | 3.97 | 28.09 |
| IMR Imricor Medical Systems Inc |
0.06 4.72% |
1.33 | - | - | 36401.21 | 17.45 | 4019.33 | -2.60 |
| AVR Anteris Technologies Global Corp |
0.50 5.88% |
9.00 | - | - | 356.02 | 2.19 | 130.34 | -5.20 |
| AVH Avita Medical Inc |
-0.11 2.13% |
5.06 | - | 9.97 | 9.59 | 7.17 | 6.76 | 15.37 |
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert Allan Phillips DMU, Ph.D.(Med), AMS, MPhil (Med), FASE, FIR | Founder, Exec. Chairman, CEO & Chief Scientist | 1953 |
| Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw | Company Sec. & Non-Exec. Director | 1957 |
| Mr. Nicholas Schicht | Gen. Mang. | 1966 |
| Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med) | Founder, Executive Chairman, CEO & Chief Scientist | 1953 |
| Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw | Company Secretary & Non-Executive Director | 1957 |
| Mr. Nicholas Schicht | General Manager | 1966 |
| Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med) | Founder, Executive Chairman, CEO & Chief Scientist | 1953 |
| Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw | Company Secretary & Non-Executive Director | 1957 |
| Mr. Nicholas Schicht | General Manager | 1966 |
| Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med) | Founder, Executive Chairman, CEO & Chief Scientist | 1953 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.